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Purpose
We investigated the efficacy of temozolomide during and after radiotherapy in Korean adults
with anaplastic gliomas without 1p/19q co-deletion.
Materials and Methods
This was a randomized, open-label, phase 2 study and notably the first multicenter trial for
Korean grade III glioma patients. Eligible patients were aged 18 years or older and had
newly diagnosed non-co-deleted anaplastic glioma with an Eastern Cooperative Oncology
Group performance status of 0-2. Patients were randomized 1:1 to receive radiotherapy
alone (60 Gy in 30 fractions of 2 Gy) (control group, n=44) or to receive radiotherapy with
concurrent temozolomide (75 mg/m2/day) followed by adjuvant temozolomide (150-200
mg/m2/day for 5 days during six 28-day cycles) (treatment group, n=40). The primary end-
point was 2-year progression-free survival (PFS). Seventy patients (83.3%) were available
for the analysis of the isocitrate dehydrogenase 1 gene (IDH1) mutation status.
Results
The two-year PFS was 42.2% in the treatment group and 37.2% in the control group. Overall
survival (OS) did not reach to significant difference between the groups. In multivariable
analysis, age was a significant risk factor for PFS (hazard ratio [HR], 2.08; 95% confidence
interval [CI], 1.04 to 4.16). The IDH1 mutation was the only significant prognostic factor for
PFS (HR, 0.28; 95% CI, 0.13 to 0.59) and OS (HR, 0.19; 95% CI, 0.07 to 0.50). Adverse
events over grade 3 were seen in 16 patients (40.0%) in the treatment group and were 
reversible. 
Conclusion
Concurrent and adjuvant temozolomide in Korean adults with newly diagnosed non-
co-deleted anaplastic gliomas showed improved 2-year PFS. The survival benefit of this reg-
imen needs further analysis with long-term follow-up at least more than 10 years.
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Introduction
Anaplastic (i.e., World Health Organization [WHO] grade
III) gliomas account for approximately 20% of adult gliomas
[1]. While surgery and radiotherapy may prolong life, prog-
nosis remains dismal, with a median survival of 2-5 years 
[2-4]. To date, despite inconclusive data, there has been
growing evidence of improved survival that the addition of
nitrosourea-based chemotherapy to radiotherapy could be
beneficial for patients with WHO grade III gliomas [5]. In
particular, adjuvant chemotherapy may be effective in 1p/
19q co-deleted anaplastic oligodendrogliomas [6,7]. Two
large randomized phase III trials of radiotherapy with or
without adjuvant procarbazine, lomustine, and vincristine
(PCV) demonstrated significant improvement in the progres-
sion-free survival (PFS) and near doubling of the overall sur-
vival (OS) to greater than 14 years in 1p/19q co-deleted
tumors treated with adjuvant radiotherapy and PCV [6,7].
However, patients with 1p/19q non-co-deleted tumors may
experience worse prognosis and faster tumor growth, requir-
ing further attention. Although some studies suggested that
1p/19q non-co-deleted tumors benefited from early chemo-
therapy, optimal indications, dosing regimens, or survival
analyses remain controversial [1]. Therefore, we focused on
these conditions and analyses and on how the CATNON trial
was distinguishable from other studies [8].
Separately, the role of chemotherapy for gliomas has been
reappraised with the development of temozolomide, and
clear benefits were found when temozolomide was added to
radiotherapy to treat newly diagnosed glioblastomas [9].
Further investigation is now being directed toward unveiling
its optimal indications, leading researchers to explore whe-
ther radiation plus temozolomide would benefit patients
with anaplastic gliomas. Some of our authors have investi-
gated the potential survival benefit and safety of concurrent
chemoradiotherapy (CCRT) with temozolomide followed by
adjuvant temozolomide for WHO grade III gliomas [10,11].
In these studies, however, the role of molecular markers,
such as chromosome 1p/19q co-deletion or O6-methylgua-
nine-DNA methyltransferase (MGMT) promoter methyla-
tion, could not be determined because of the small sample
size. These results prompted the authors to conduct a multi-
institutional trial.
We investigated the efficacy of temozolomide during and
after radiotherapy in Korean adult patients with newly diag-
nosed WHO grade III gliomas without the 1p/19q co-dele-
tion. In this study, the authors studied the role of temozo-
lomide in patients who were expected to have worse prog-
noses according to the status of chromosome 1p/19q, i.e.,
1p/19q non-co-deleted tumors. The treatment group (sur-
gery plus CCRT with temozolomide followed by six cycles
of adjuvant temozolomide) was compared to the control
group (surgery plus radiotherapy alone) in terms of the effi-
cacy and safety of temozolomide.
Materials and Methods
1. Study design and patients
The KOREANA study was a multicenter study performed
by the Korean Neuro-Oncology Group of Korean Society for
Neuro-Oncology (KSNO). The trial was a randomized, open-
label, phase 2 study to evaluate the efficacy between only 
radiotherapy versus combination therapy with radiotherapy
and temozolomide in Korean adult patients with newly 
diagnosed supratentorial grade III gliomas without the 1p/
19q co-deletion. The protocol was registered at clinicaltri-
als.gov (NCT01534845).
Patients with newly diagnosed, histologically proven
supratentorial anaplastic gliomas, i.e., WHO grade III glioma
without the 1p/19q co-deletion was eligible to participate in
this study. The inclusion criteria were as follows: diagnosis
of anaplastic gliomas according to the 2007 WHO criteria;
age  18 years; Eastern Cooperative Oncology Group per-
formance status of 0 or 1; stable or decreasing dose of steroids
for  5 days prior to randomization; recursive partitioning
analysis classification of III, IV, or V; and adequate hemato-
logic, renal, and hepatic functions, including an absolute
neutrophil count > 1,500/µL, platelet count  100,000/µL,
serum creatinine < 1.7 mg/dL, bilirubin level  2.0 mg/dL,
and aspartate aminotransferase/alanine aminotransferase 
 2.5the upper limit of the normal range of each institution.
The exclusion criteria consisted of having prior chemother-
apy within the last 5 years, having prior radiotherapy of the
head and neck area, receiving concurrent investigational
agents or having received an investigational agent within 30
days prior to randomization, having planned surgery for
other diseases, having a history of malignancy with the 
exception of cervical carcinoma in situ or basal cell carcinoma
of the skin, being pregnant or lactating, refusing to use effec-
tive contraception, having concurrent illness that would 
interfere with the prescribed treatment, and being unable to
undergo gadolinium-based magnetic resonance imaging
(MRI).
2. Treatment schema
At enrollment, the diagnosis of anaplastic glioma had to
be confirmed at each institution. In addition, the tumor 
material was submitted for assessment of the 1p/19q co-dele-
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tion status and review of pathology by pathologist (G.C.) at
the central laboratory. The 1p/19q co-deletion status was 
assessed by fluorescent in situ hybridization [12]. After iden-
tifying the status of the 1p/19q co-deletion, patients were
screened for inclusion and then assigned in equal numbers
to receive CCRT with temozolomide followed by adjuvant
temozolomide (treatment group [arm A]) or to receive radio-
therapy alone (control group [arm B]). The clinical data were
collected and validated with a web-based clinical research
management platform (Velos Inc., Fremont, CA).
All patients received fractionated focal irradiation in daily
fractions of 2 Gy given 5 days per week for 6 weeks, for a
total of 60 Gy. When given concurrently with radiotherapy,
temozolomide was given daily from the first to the last day
of radiotherapy, including on non-radiotherapy weekend
days, at a dose of 75 mg/m2 for a maximum of 6 weeks. As
adjuvant chemotherapy, temozolomide was started 4 weeks
after completion of radiotherapy for a maximum of six cycles.
Patients received 150 mg/m2 temozolomide on days 1-5 of
the first cycle and 200 mg/m2 on days 1-5 of subsequent 
cycles if no or minor toxicity was seen during the first cycle,
and dose modifications could be made as described else-
where [9]. Treatment after disease progression, the rescue
regimen will be administered: the use of temozolomide was




Patients were followed up weekly during radiotherapy,
every 2 weeks during adjuvant temozolomide treatment, and
every 3 or 4 months after the completion of all treatment. 
Tumors were assessed with MRI and steroid dose. MRI was
performed 4 weeks after the end of radiotherapy and every
3 months until the second year and every 6 months thereafter
until disease progression. Radiographic response is deter-
mined in comparison to the tumor measurement obtained at
pretreatment baseline measurements as a reference and is
categorized into four groups using new criteria proposed by
the Response Assessment in Neuro-Oncology working
group [13]. Patients with possible pseudoprogression were
kept on current treatment and re-evaluated 4 weeks there-
after to clarify the response. Steroid dose was reviewed at
every outpatient visit. Clinical evaluation with adverse
events was scored with the National Cancer Institute Com-
mon Toxicity Criteria for Adverse Event ver. 4.0.
The evaluation of health-related quality of life was asses-
sed using the European Organization for Research and Treat-
ment of Cancer quality-of-life questionnaire (QLQ-C30) and
brain module (QLQ-BN20). Questionnaires were completed
on paper at baseline (prior to randomization) and subse-
quently at all visits when MRI was performed. Data on
health-related quality of life will be reported separately.
4. Outcomes
The primary endpoint was 2-year PFS. Landmark PFS was
also analyzed. PFS was calculated from the date of random-
ization to the date of first tumor progression or death
whichever was earlier, with censoring of patients who were
lost to follow-up. Two-year PFS was defined as the survival
rate at the second year from randomization.
The second endpoints were overall PFS and OS adjusted
for stratification factors, health-related quality of life out-
comes, and adverse events. OS was defined as the time from
randomization to the date of death from any cause.
5. Statistical analysis
Baseline characteristics, details of treatments and adverse
events were expressed as the mean with standard deviation
for continuous variables and the frequency with percentage
for categorical variables. The comparisons between arm A
and arm B were carried out using Student’s t test, Pearson’s
chi-square or Fisher exact test, as appropriate. The survival
curves were estimated using the Kaplan-Meier method, and
the difference between survival curves was evaluated using
the log-rank test. The Kaplan-Meier estimates at fixed time
points (3, 6, 12, 18, and 24 months for PFS and 12, 24, and 60
months for OS) were compared based on the Z test. The Z
test statistics used variance estimators calculated with Green-
wood’s formula. To explore the prognostic factors for PFS
and OS, univariable Cox proportional hazards models were
performed. A multivariable Cox proportional hazard model
with a backward elimination criterion of p > 0.2 was applied.
The 2-year PFS, which was the primary outcome of the study,
was considered statistically significant when the one-sided
p-value was less than 0.2. Otherwise, the results were regar-
ded as statistically significant when the two-sided p-value
was less than 0.05. Statistical analyses were performed using
SAS ver. 9.4 (SAS Institute Inc., Cary, NC).
6. Ethical statement
A total of 14 Korean institutions participated in this study
with ethics approval from their institutional review boards
before enrollment started. All patients gave written informed
consent according to national guidelines. Patients were not
compensated for their participation.
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CCRT with temozolomide Radiotherapy p-valueplus adjuvant temozolomide alone
Total dose of radiotherapy (Gy) 60.1±1.3 60.2±3.6 0.771a)
Duration of radiotherapy (wk) 6.3±0.9 6.1±0.7 0.188a)
Duration of temozolomide with CCRT (wk) 5.7±0.9 - -
Duration of temozolomide after CCRT (cycle, missing=2) 5.3±1.6 - -
Response of treatment at TMZ or after radiotherapy cycle 1 (missing=1)
Complete response 2 (5.1) 1 (2.3) 0.869b)
Partial response 9 (23.1) 12 (27.3)
Stable disease 22 (56.4) 24 (54.6)
Progressive disease 3 (7.7) 5 (11.4)
Not assessed 3 (7.7) 2 (4.5)
Response of treatment at end of treatment (missing=19)
Complete response 0 ( 1 (3.0) 0.851c)
Partial response 7 (21.2) 5 (15.2)
Stable disease 19 (57.6) 20 (60.6)
Progressive disease 6 (18.2) 6 (18.2)
Not assessed 1 (3.0) 1 (3.0)
CCRT, concurrent chemoradiotherapy; TMZ, temozolomide. a)Student’s t test, b)Chi-square test, c)Fisher exact test. 
Table 2. Details and intensities of the treatment 
Total CCRT with temozolomide plus Radiotherapy p-value(n=84) adjuvant temozolomide (n=40) alone (n=44)
Age (yr) 44.7±13.2 44.7±13.3 44.8±13.2 0.980a)
Sex
Male 46 (54.8) 23 (57.5) 23 (52.3) 0.631b)
Female 38 (45.2) 17 (42.5) 21 (47.7)
ECOG performance status
0 34 (40.5) 12 (30.0) 22 (50.0) 0.143c)
1 44 (52.4) 24 (60.0) 20 (45.5)
2 6 (7.14) 4 (10.0) 2 (4.5)
Extent of tumor resection
Gross total resection 37 (44.1) 17 (42.5) 20 (45.5) 0.681b)
Subtotal resection 17 (20.2) 9 (22.5) 8 (18.2)
Partial resection 14 (16.7) 5 (12.5) 9 (20.5)
Biopsy only 16 (19.1) 9 (22.5) 7 (15.9)
MGMT promotor methylation
Unmethylation 42 (64.6) 21 (65.6) 21 (63.6) 0.867b)
Methylation 23 (35.4) 11 (34.4) 12 (36.4)
Missing 19 ( 8 ( 11 (
IDH1 mutation
Negative 44 (62.9) 22 (64.7) 22 (61.1) 0.756b)
Positive 26 (37.1) 12 (35.3) 14 (38.9)
Missing 14 ( 6 ( 8 (
Follow-up duration, median (range, mo) 44.9 (2.8-71.1) 52.9 (3.6-69.7) 42.1 (2.8-71.1) 0.209d)
Values are presented as mean±standard deviation or number (%) unless otherwise indicated. CCRT, concurrent chemora-
diotherapy; ECOG, Eastern Cooperative Oncology Group; MGMT, O6-methylguanine-DNA methyltransferase; IDH1, isoc-
itrate dehydrogenase 1. a)Student’s t test, b)Chi-square test, c)Fisher exact test, d)Log-rank test.
Table 1. Baseline characteristics of patients 
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Results
1. Patients and treatment
From March 2012 to February 2015, 146 patients were
screened, and 90 patients were randomly assigned to treat-
ment groups. Six patients did not start treatment because of
either consent withdrawal (n=4) or disease progression
(n=2), and a total of 84 were included in the final analysis.
There were 46 males (54.8%) and 38 females (45.2%). The
mean age of patients was 44.7±13.2 years. Fifty-four patients
(64.3%) underwent removal of over 75% of the tumor mass,
including gross total removal or subtotal removal, and 30 
patients (35.8%) underwent partial removal or biopsy only.
The results were available for the MGMT promoter methy-
lation status for 65 of 84 patients (77.4%) and the isocitrate
dehydrogenase 1 gene (IDH1) mutation status for 70 of 84
patients (83.3%) at the time of the preliminary analysis. 
Patients were randomly assigned to each treatment group
according to the study protocol as follows: 44 patients recei-
ved radiotherapy alone, and 40 patients received CCRT with
temozolomide plus adjuvant temozolomide. The character-
istics of patients in these two groups were well balanced at
the baseline (Table 1).
In this trial, radiotherapy was completed in all but one of
84 patients (1.2%) in whom it was started. Among 40 patients
assigned to the CCRT with temozolomide plus adjuvant
temozolomide group, 39 patients (97.5%) completed radio-
therapy with concurrent temozolomide. The mean therapeu-
tic radiation dose was 60.1±1.3 Gy, and the mean duration of
temozolomide with CCRT was 5.7±0.9 weeks. After exclud-
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Fig. 1.  Kaplan-Meier curve of progression-free survival (A) and overall survival (B). CCRT, concurrent chemoradiotherapy;























































CCRT with TMZ+TMZ 6 cycles
RT only
1.0
CCRT with temozolomide Radiotherapy p-valuea)plus adjuvant temozolomide alone
Progression-free survival
Median (mo) 19.5 15.9
At 3 mo (%) 92.5 90.7 0.773 
At 6 mo (%) 87.3 79.1 0.317 
At 12 mo (%) 71.4 55.8 0.139 
At 18 mo (%) 58.2 41.9 0.137 
At 24 mo (%) 42.2 37.2 0.652 
Overall survival 
Median (mo) 43.7 36.7
At 12 mo (%) 84.0 95.2 0.100 
At 24 mo (%) 63.7 63.0 0.945 
CCRT, concurrent chemoradiotherapy. a)Landmark analysis (Z test). 
Table 3. Progression-free survival and overall survival according to treatment 
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ing one patient who progressed before starting adjuvant
temozolomide, 32 of 38 patients (84.2%) completed adjuvant
temozolomide with a mean of 5.3±1.6 cycles. Table 2 sum-
marizes the details of the treatment delivered to the two
treatment groups. There were no statistically significant dif-
ferences in total radiation dose, duration of radiotherapy, or
response to treatment between the treatment groups.
2. Tumor control and survival
After treatment, the objective response rate (complete res-
ponse and partial response) and the tumor control rate (com-
plete response, partial response, and stable disease) among
patients who received radiotherapy alone were 18.8% and
81.3%, respectively. For patients who received CCRT with
temozolomide plus adjuvant temozolomide, the response
rate and the tumor control rate were 21.9% and 81.3%, res-
pectively. The response to each treatment at the end of treat-
ment showed no statistical significance (Table 2).
Kaplan-Meier survival curves of the patients according to
the treatment are illustrated in Fig. 1. CCRT with temozolo-
mide plus adjuvant temozolomide was associated with an
improved 2-year PFS (log-rank p=0.186), as we set one-sided
type I error as 0.2, but not with OS. For patients who received
radiotherapy alone, the median PFS was 15.9 months, and
the 2-year PFS was 37.2%. The median OS was 36.7 months,
and the 12- and 24-month OS rates were 95.2% and 63.0%,
respectively. Among patients who received CCRT with
temozolomide plus adjuvant temozolomide, the median PFS
was 19.5 months, and the 2-year PFS was 42.2%. The median
OS was 43.7 months, and the 12- and 24-month OS rates were
84.0% and 63.7%, respectively. The PFS and OS landmark
values are presented in Table 3.
Prognostic factors, including the treatment, extent of resec-
tion, age, sex, methylation of the MGMT promoter, and IDH1
mutation were analyzed. In the univariable analysis, the 
extent of resection, age, and IDH1mutation were significant
prognostic factors for PFS. By the multivariable analysis, the
hazard ratio (HR) for PFS adjusted for baseline stratification
factors among patients with IDH1 mutation was 0.28 (95%
confidence interval [CI], 0.13 to 0.59; p=0.001). Age was a sig-
nificant risk factor for PFS (HR, 2.08; 95% CI, 1.04 to 4.16;
p=0.039). For OS, the significant prognostic factor in the uni-
variable analysis was the extent of resection, the methylation
Kihwan Hwang, Temozolomide for Non-co-deleted Grade III Gliomas 
Fig. 2.  Kaplan-Meier curve of progression-free survival (A, B) and overall survival (C, D) according to O6-methylguanine-
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of the MGMT promoter, and IDH1mutation. However, IDH1
mutation was the only significant prognostic factor for OS
(HR, 0.19; 95% CI, 0.07 to 0.50; p=0.001) by multivariable
analysis (Table 4).
3. Subgroup analysis according to genotypical characteris-
tics
Since we started this trial, mutations in IDH1 have been
widely known to be associated with improved outcomes and
incorporated into the 2016 WHO classification of glioma
[14,15]. To clarify whether the presence of MGMT promoter
methylation or IDH1mutation could show differences in sur-
vival according to treatment, PFS and OS according to treat-
ment and genotypical characteristics were analyzed. In a
subgroup analysis, however, Kaplan-Meier survival curves
showed no significant differences between both treatment
groups according to the MGMT promoter methylation status
(Fig. 2) or IDH1mutation status (Fig. 3).
4. Toxic effects
There were 24 patients, 16 of 40 patients (40.0%) in the
treatment group and eight of 44 patients (18.2%) in the con-
trol group, who had adverse events over grade 3 after treat-
ment. The difference between each group was statistically
significant (p=0.027). During CCRT with temozolomide plus
adjuvant temozolomide, 11 patients (27.5%) showed nervous
system disorder (including 3 hydrocephalus and 2 seizures),
five patients (12.5%) exhibited procedural complications 
(including 3 radiation recall reactions), three patients (7.5%)
experienced investigations (including 2 hematological toxic-
ities), and so on. In the two patients (5.0%) with reported
hematological toxicity category, one patient had leukocy-
topenia and another patient had thrombocytopenia. For pati-
ents who underwent radiotherapy alone, there were four
patients (9.1%) with nervous system disorders, three patients
(6.8%) with musculoskeletal disorders, two patients (4.5%)
with psychiatric disorders, and so on. The distribution of the
adverse events associated with the treatment is presented in
Table 5.
Cancer Res Treat. 2020;52(2):505-515
Fig. 3.  Kaplan-Meier curve of progression-free survival (A, B) and overall survival (C, D) according to isocitrate dehydro-
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Discussion
This phase 2 trial of 84 patients demonstrated significant
benefits for PFS with temozolomide during and after radio-
therapy in patients with newly diagnosed WHO grade III
glioma without the chromosome 1p/19q co-deletion. Alth-
ough there was no significant difference in OS between the
two arms, our further analysis showed that age over 40 years
was an independent risk factor for PFS (HR, 2.08) and that
the presence of IDH1 mutation had a risk reduction for PFS
(HR, 0.28) and OS (HR, 0.19).
The standard treatment protocol for WHO grade III glio-
mas has developed for many decades. Based on observations
from previous studies, WHO grade III gliomas have been 
regarded as at least as chemosensitive as glioblastomas, and
patients postoperatively treated with radiotherapy alone or
chemotherapy alone fared worse than those treated with con-
current or adjuvant chemotherapy with radiotherapy [16,17].
Traditionally, anaplastic oligodendrogliomas are generally
known to be chemosensitive and have had high rates of 
radiographic response in several trials after treatment with
PCV [18]. However, chemotherapy with PCV has shown 
unacceptable toxicity, and the concurrent or adjuvant setting
remains controversial. In the meantime, the efficacy found
with adjuvant chemotherapy to radiotherapy for anaplastic
astrocytoma, i.e., the 1p/19q non-co-deleted anaplastic glio-
mas in the revised 2016 WHO classification, seemed more
doubtful. Several studies found no significant survival ben-
efits for adjuvant PCV [19-21]. However, CATNON trial
identified adjuvant temozolomide prolongs survival for non-
co-deleted anaplastic gliomas after radiotherapy [8]. In addi-
tion, our study showed the possibility that CCRT with temo-
zolomide followed by adjuvant temozolomide has survival
benefits for patients with WHO grade III gliomas.
This study adds to the literature for several reasons. This
trial is the first investigator-initiated, multi-institutional, ran-
domized trial for Korean adult patients with grade III glioma.
For non-glioblastoma, compared to Whites, the incidence
rate among Asians was substantially lower [22]. However,
there have been fewer clinical trials only for Asian popula-
tion. Especially, Koreans are one ethnic family, so long-term
follow-up for unique ethnic group would be worth studying
in terms of racial variation. And There should not be admin-
istrative, financial, and/or systemic difficulties in terms of
performing clinical trials. We established a well-made system
for this study and produced meaningful results. In addition,
this trial included only patients with anaplastic gliomas with-
out the chromosome 1p/19q co-deletion. Since patients with-
out 1p/19q co-deletion gliomas had worse outcomes in the
trials of PCV chemotherapy for anaplastic oligodendrog-
lioma, we decided to take this approach [7,18,23]. Until now,
there have been limited trials examining the efficacy and
safety of temozolomide for patients with WHO grade III
gliomas based on prospective molecular stratification. Fur-
thermore, for patients with WHO grade III gliomas, the 
addition of temozolomide to radiotherapy, rather than PCV,
is unusual [24]. Available data demonstrate with fair clarity
that temozolomide is less toxic, easier to prescribe and less
complicated for patients [25]. Although patients in this trial
had 1p/19q non-co-deletion anaplastic gliomas, temozolo-
mide showed a clear benefit. Finally, we assessed not only
the treatment outcome itself but also the consequence of the
quality-of-life for patients who underwent the treatment pro-
tocol. The results of the quality-of-life will be reported sepa-
rately.
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Total CCRT with temozolomide Radiotherapy plus adjuvant temozolomide alone
Gastrointestinal disorders 3 (3.8) 3 (7.5) 0 (
General disorders and administration site conditions 1 (1.3) 0 ( 1 (2.3)
Immune system disorders 1 (1.3) 1 (2.5) 0 (
Infections and infestations 1 (1.3) 1 (2.5) 0 (
Injury, poisoning, and procedural complications 6 (7.5) 5 (12.5) 1 (2.3)
Investigations 3 (3.8) 3 (7.5) 0 (
Metabolism and nutrition disorders 4 (5.0) 3 (7.5) 1 (2.3)
Musculoskeletal and connective tissue disorders 4 (5.0) 3 (7.5) 3 (6.8)
Nervous system disorders 15 (18.8) 11 (27.5) 4 (9.1)
Psychiatric disorders 2 (2.5) 0 ( 2 (4.5)
Renal and urinary disorders 1 (1.3) 0 ( 1 (2.3)
Vascular disorders 1 (1.3) 0 ( 1 (2.3)
Values are presented as number (%). CCRT, concurrent chemoradiotherapy.
Table 5. Adverse event over grade 3 
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At the time of the beginning of this trial, genotypical char-
acteristics were not considered in the WHO 2007 classifica-
tion of glioma [26]. In 2009, mutations in IDH1 and IDH2
were reported to occur in 70%-80% of all grade II and III dif-
fuse gliomas [14]. These mutations are associated with 
improved survival and are now the cornerstone of the revi-
sed WHO classification of gliomas [15,27,28]. Later, we incor-
porated analysis of the IDH1 mutation status and again
demonstrated a significant survival benefit for patients with
IDH1mutation. However, in a subgroup analysis of MGMT
promoter methylation and IDH1mutation, there were no sig-
nificant differences according to treatment modalities. This
result could be due to the small sample size, or those markers
might not have predictive value for benefit from CCRT with
temozolomide. Further analysis with a large sample size is
needed.
Our study has some limitations. (1) The number of patients
remains relatively small compared with other trials for pati-
ents with adult gliomas. A future study with a larger sample
size and more statistical power is necessary to validate find-
ings from this study. (2) Only 2 years have passed since the
last participant was enrolled in this study, and a more long-
term follow-up is needed. In other trials for patients with
WHO grade III gliomas, the survival curves begin to diverge
5-6 years after randomization. The lack of significance may
have been due to limitations of follow-up periods, and the
survival benefit of our regimen needs further analysis with
long-term follow-ups. (3) As we sorted patients according to
the WHO 2007 classification of glioma, there was a slight het-
erogeneity of the patient population. WHO grade III gliomas
are now known to consist of heterogeneous groups of differ-
ent histologic features, biological behaviors, and prognoses.
As relevant molecular markers show their implications in 
response to therapy and survival, future studies should be
based on discriminated molecular factors.
In conclusion, temozolomide during and after radiother-
apy in Korean adult patients with newly diagnosed non-
co-deleted WHO grade III gliomas showed an improved 2-
year PFS. Temozolomide, given its superior tolerability com-
pared with PCV, showed acceptable adverse events. The
survival benefit of this regimen requires further analysis with
long-term follow-up at least more than 10 years. More pro-
spective studies into the biology and prognostic significance
of MGMT promoter methylation and other molecular mark-
ers are also required.
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